MedTrace Logo

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

NCT06172660 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3750

Last updated 2025-08-14

No results posted yet for this study

Summary

The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?

Conditions

  • RSV Infection

Interventions

DRUG

Nirsevimab

Immunoprophylaxis against RSV

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Carlos R Oliveira, MD · Yale University

Eligibility

Max Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-28
Primary Completion
2028-12-30
Completion
2028-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06172660 on ClinicalTrials.gov